THE NICKLES GROUP, LLC for EMERGENT BIOSOLUTIONS
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2026. Opioid and heroin addiction legislation, naloxone access and awareness.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Health Issues HCR
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2026, Opioid crisis legislation, naloxone access and awareness, FY2026 NDAA provisions related to biological and chemical defense and access to naloxone.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
| MARY BETH SAVARY TAYLOR | — |
Defense DEF
National Defense Authorization Act for FY2026, provisions related to biological and chemical defense and access to naloxone.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.